Treatment of neurobrucellosis: What is known and what remains to be answered

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 6, 2007, Pages 983-990

  Pappas, Georgios ^a   Akritidis, Nikolaos ^b   Christou, Leonidas ^c  

^a Institute of Continuing Medical Education of Ioannina   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Brucellosis; Ceftriaxone; CNS; Corticosteroid; Meningitis; Neurobrucellosis; Streptomycin; Treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; DEXAMETHASONE; DOXYCYCLINE; GENTAMICIN; LATAMOXEF; PREDNISOLONE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE; TIGECYCLINE;

ANTIBIOTIC THERAPY; BLOOD BRAIN BARRIER; BRUCELLOSIS; CENTRAL NERVOUS SYSTEM INFECTION; CORTICOSTEROID THERAPY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INDIVIDUALIZATION; MEDICAL LITERATURE; MONOTHERAPY; NEUROTOXICITY; REAL TIME POLYMERASE CHAIN REACTION; REFERENCE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; ZOONOSIS;

ANTI-BACTERIAL AGENTS; BRUCELLOSIS; CEFTRIAXONE; CENTRAL NERVOUS SYSTEM BACTERIAL INFECTIONS; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; HUMANS; RIFAMPIN; STREPTOMYCIN;

EID: 37349084564     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.6.983     Document Type: Review

References (55)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. The new global map of human brucellosis. Lancet Infect. Dis. 6(2), 91-99 (2006).
2. Corbel MJ. Brucellosis: an overview. Emerg. Infect. Dis. 3(2), 213-221 (1997).
3. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N. Engl. J. Med. 352(22), 2325-2336 (2005).
4. Young EJ. An overview of human brucellosis. Clin. Infect. Dis. 21(2), 283-289 (1995).
5. Colmenero JD, Reguera JM, Martos F et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 75(4), 195-211 (1996).
6. Pappas G, Akritidis N, Tsianos E. Effective treatments in the management of brucellosis. Expert Opin. Pharmacother. 6(2), 201-209 (2005).
7. Memish ZA, Balkhy HH. Brucellosis and international travel. J. Travel Med. 11(1), 49-55 (2004).
8. Pappas G, Panagopoulou P, Christou L, Akritidis N. Brucella as a biological weapon. Cell. Mol. Life Sci. 63(19-20), 2229-2236 (2006).
9. McLean DR, Russell N, Khan MY. Neurobrucellosis: clinical and therapeutic features. Clin. Infect. Dis. 15(4), 582-590 (1992).
10. Spink WW. The Nature of Brucellosis. University of Minnesota Press, MN, USA 146-190 (1956).
11. Fincham RW, Sahs AL, Joynt RJ. Protean manifestations of nervous system brucellosis. Case histories of a wide variety of clinical forms. JAMA 184, 269-275 (1963).
12. Shakir RA, Al-Din AS, Araj GF, Lulu AR, Mousa AR, Saadah MA. Clinical categories of neurobrucellosis. A report on 19 cases. Brain 110(Pt 1), 213-223 (1987).
13. Gorvel JP, Moreno E. Brucella intracellular life: from invasion to intracellular replication. Vet. Microbiol. 90(1-4), 281-297 (2002).
14. Akova M, Gur D, Livermore DM, Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob. Agents Chemother. 43(5), 1298-1300 (1999).
15. Navarro E, Segura JC, Castano MJ, Solera J. Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. Clin. Infect. Dis. 42(9), 1266-1273 (2006).
16. Boura P, Skendros; P, Kountouras J. Zacharioudaki E, Tsapas T. Effect of bacterial extracts on the immunologic profile in chronic relapsing brucellosis patients. Int. J. Immunopathol. Pharmacol. 12(2), 103-111 (1999).
17. Billard E, Cazevieille C, Dornand J, Gross A. High susceptibility of human dendritic cells to invasion by the intracellular pathogens Brucella suis, B. abortus, and B. melitensis, Infect. Immun. 73(12), 8418-8424 (2005).
18. Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int. J. Antimicrob. Agents 26, 101-105 (2005)
19. Sande MA. Antibiotic therapy of bacterial meningitis: lessons we've learned. Am. J. Med. 71(4), 507-510 (1981).
20. Palenque E, Otero JR, Noriega AR. In vitro susceptibility of Brucella melitensis to new cephalosporins crossing the blood-brain barrier. Antimicrob. Agents Chemother. 29(1), 182-183 (1986).
21. Bosch J, Linares J, Lopez de Goicoechea MJ, Ariza J, Cisnal MC, Martin R. In vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitenssis. J. Antimicrob. Chemother. 17(4), 459-461 (1986).
22. Bodur H, Balaban N, Aksaray S et al. Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand. J. Infect. Dis. 35(5), 337-338 (2003).
23. Baykam. N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B. In vitro antimicrobial susceptibility of Brucella species. Int. J. Antimicrob. Agents 23(4), 405-407 (2004).
24. Tanyel E, Coban AY, Koruk ST et al. Actual antibiotic resistance pattern of Brucella melitensis in central Anatolia. An update from an endemic region. Saudi Med. J. 28 (8), 1239-1242 (2007).
25. al-Idrissi HY, Uwaydah AK, Danso KT, Qutub H, al-Mousa MS. Ceftriaxone in the treatment of acute and subacute human brucellosis. J. Int. Med. Res. 17(4), 363-368 (1989).
26. Lang R, Dagan R, Potasman I, Einhorn M, Raz R. Failure of ceftriaxone in the treatment of acute brucellosis. Clin. Infect. Dis. 14(2), 506-509 (1992).
27. Young EJ. Human brucellosis. Rev. Infect. Dis. 5(5), 821-842 (1983).
28. Pappas G, Seitaridis S, Akritidis N, Tsianos E. Treatment of brucella spondylitis: lessons from an impossible meta-analysis and initial report of efficacy of a fluoroquinolone-containing regimen. Int. J. Antimicrob. Agents 24(5), 502-507 (2004).
29. Al-Sous MW, Bohlega S, Al-Kawi MZ, Alwatban J, McLean DR. Neurobrucellosis: clinical and neuroimaging correlation. Am. J. Neuroradiol. 25(3), 395-401 (2004).
30. Adeva-Bartolome MT, Montes-Martinez I, Castellanos-Pinedo F, Zurdo-Hernandez JM, de Castro-Garcia FJ. Neurobrucellosis: four case reports. Rev. Neurol. 41(11), 664-666 (2005).
31. Solera J, Geijo P, Largo J et al. A randomized, double-blind study to assess the optimal duration of doxycycline treatment for human brucellosis. Clin. Infect. Dis. 39(12), 1776-1782 (2004).
32. Solera J, Lozano E, Martinez-Alfaro E et al. Brucellar spondylitis: review of 35 cases and literature survey. Clin. Infect. Dis. 29(6), 1440-1449 (1999).
33. Fitch MT, van de Beek D. Emergency diagnosis and treatment of adult meningitis. Lancet Infect. Dis. 7 (3), 191-200 (2007).
34. Samdani PG, Patil S. Neurobrucellosis. Indian Pediatr. 40(6), 565-568 (2003).
35. Davis CE, Troy SB, Torma I et al. Brucellosis - correspondence. N. Engl. J. Med. 353(10), 1071-1072 (2005).
36. Ayala-Gaytan JJ, Ortegon-Baqueiro H, de la Maza M. Brucella malitensis cerebellar abscess. J. Infect. Dis. 160(4), 730-732 (1989).
37. Colmenero JD, Queipo-Ortuno MI, Reguera JM, Baeza G, Salazar JA, Morata P. Real time polymerase chain reaction: a new powerful tool for the diagnosis of neurobrucellosis. J. Neurol. Neurosurg. Psychiatry 76(7), 1025-1027 (2005).
38. Morata P, Queipo-Ortuno MI, Reguera. JM, Garcia-Ordonez MA, Pichardo C, Colmenero JD. Posttreatment follow-up of brucellosis by PCR assay. J. Clin. Microbiol. 37(12), 4163-4166 (1999).
39. Guerreiro CA, Scaff M, Callegaro D, Facure NO, Dianin VM. Neurobrucellosis: report of 3 cases. Arq. Neuropsiquiatr. 39(2), 203-213 (1981).
40. Bashir R, Al-Kawi MZ, Harder EJ, Jinkins J. Nervous system brucellosis: diagnosis and treatment. Neurology 35(11). 1576-1581 (1985).
41. Bouza E, Garcia de la Torre M, Parras F, Guerrero A, Rodriguez-Creixems M, Gobernado J. Brucellar meningitis. Rev. Infect. Dis. 9(4), 810-822 (1987).
42. al Deeb SM, Yaqub BA, Sharif HS, Phadke JG. Neurobrucellosis: clinical characteristics, diagnosis, and outcome. Neurology 39(4), 498-501 (1989).
43. Lubani MM, Dudin KI, Araj GF, Manandhar DS, Rashid FY. Neurobrucellosis in children. Pediatr. Infect. Dis. J. 8(2), 79-82 (1989).
44. Sanchez-Sousa A, Torres C, Campello MG et al. Serological diagnosis of neurobrucellosis. J. Clin. Pathol. 43(1), 79-81 (1990).
45. al-Eissa YA. Clinical and therapeutic features of childhood neurobrucellosis. Scand. J. Infect. Dis. 27(4), 339-343 (1995).
46. Estevao MH, Barosa LM, Matos LM, Barroso AA, da Mota HC. Neurobrucellosis in children. Eur. J. Pediatr. 154(2), 120-122 (1995).
47. Marzo Sola ME, Calderon Giron C, Ayuso Blanco T, Uson Martin M, Marta Moreno ME, Bestue Cardiel M. Neurobrucellosis. A report of 13 cases. Neurologia 10(9), 375-379 (1995).
48. Omar FZ, Zuberi S, Minns RA. Neurobrucellosis in childhood: six new cases and a review of the literature. Dev. Med. Child. Neurol. 39(11), 762-765 (1997).
49. Bellissima P, Turturici MA. Neurobrucellosis: clinical and therapeutic features. Infez. Med. 6(1), 25-30 (1998).
50. Akdeniz H, Irmak H, Anlar O, Demiroz AP. Central nervous system brucellosis: presentation, diagnosis and treatment. J. Infect. 36(3), 297-301 (1998).
51. Kochar DK, Kumawat BL, Agarwal N et al. Meningoencephalitis in brucellosis. Neurol. India 48(2), 170-173 (2000).
52. Aygen B, Doganay M, Sumerkan B, Yildiz O, Kayabas U. Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patients. Med. Malad. Infect. 32(2002), 485-493 (2002).
53. Bodur H, Erbay A, Akinci E, Colpan A, Cevik MA, Balaban N. Neurobrucellosis in an endemic area of brucellosis. Scand. J. Infect. Dis. 35(2), 94-97 (2003).
54. Eren S, Bayam G, Ergonul O et al. Cognitive and emotional changes in neurobrucellosis. J. Infect. 53(3), 184-189 (2006).
55. Mantur BG, Biradar MS, Bidri RC et al. Protean clinical manifestations and diagnostic challenges of human brucellosis in adults: 16 years' experience in an endemic area. J. Med. Microbiol. 55(Pt 7), 897-903 (2006).